Fruquintinib Price in 2023

Fruquintinib (Fruquintinib) is an oral small molecule targeted inhibitor that belongs to a class of multicaseokinase inhibitors. It is a drug used to treat advanced gastric and colorectal cancer, especially when the patient has metastases or is inoperable despite other treatments.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.

Fruquintinib is unique in that it highly selectively inhibits the activity of vascular endothelial growth factor receptor (VEGFR), thereby blocking the formation and growth of tumor blood vessels. This mechanism makes fruquintinib a potent anti-angiogenic drug, inhibiting tumor growth and spread by reducing the tumor's dependence on the blood supply.

Clinical studies have shown that fruquintinib has achieved significant clinical effects in the treatment of advanced colorectal cancer and gastric cancer. Patients generally observe tumor shrinkage and improvement in condition after receiving fruquintinib treatment. Fruquintinib has less toxic side effects than other treatments, making it a relatively safe treatment option.

Although fruquintinib has shown potential positive effects in the treatment of advanced cancer, more research is needed in a broad range of clinical practice to gain insight into its long-term efficacy and safety. In addition, as cancer research continues to deepen, the application fields of fruquintinib may continue to expand, providing effective treatment options for more patients.